Janssen’s CAR-T shows 100% response rate in multiple myeloma
Longer-term follow-up data from CARTITUDE-1 study show an overall response rate of 100% while 86% experienced a complete response
Read More
Tag: JNJ-4528
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
